Role of peroxisome proliferator-activated receptors in the control of alcohol dependence and concomitant liver pathology
https://doi.org/10.29235/1814-6023-2019-16-2-244-256
Abstract
The article is aimed to summarize the scattered data on the role of peroxisome proliferator-activated receptors (PPAR) and the possibility of using PPAR’s agonists for treatment of alcohol dependence and alcoholic liver disease. Earlier it was shown that some PPAR agonists can reduce ethanol consumption and preference in rodents. Several hypotheses considering the antialcoholic activity of PPAR agonists and the roles of PPAR in the development of alcohol dependence were discussed. In light of these data, the therapeutic potential of PPARs agonists as an agent for the treatment of alcoholism, has been reviewed.
About the Authors
I. N. Semenenya
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
Igor N. Semenenya – D. Sc. (Med.), Professor, Director
50, BLK, 230030, Grodno
A. H. Shlyahtun
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
Alexej H. Shlyahtun – Head of the Laboratory
50, BLK, 230030, Grodno
H. F. Raduta
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
Helena F. Raduta – Senior researcher
50, BLK, 230030, Grodno
References
1. Miller P. M., Book S. W., Stewart S. H. Medical treatment of alcohol dependence: a systematic review. International Journal of Psychiatry, 2011, vol. 42, no. 3, pp. 227–266. https://doi.org/10.2190/PM.42.3.b
2. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, vol. 68, no. 5, pp. 879–887. https://doi.org/10.1016/0092-8674(92)90031-7
3. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, vol. 347, no. 6294, pp. 645–650. https://doi.org/10.1038/347645a0
4. Kliewer S. A., Forman B. M., Blumberg B., Ong E. S., Borgmeyer U., Mangelsdorf D. J., Umesono K., Evans R. M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences, 1994, vol. 91, no. 15, pp. 7355–7359. https://doi.org/10.1073/pnas.91.15.7355
5. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutrition Journal, 2014, vol. 13, аrt. 17. https://doi.org/10.1186/1475-2891-13-17
6. Becker J., Delayre-Orthez C., Frossard N., Pons F. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation. Pulmonary Pharmacology and Therapeutics, 2008, vol. 21, no. 2, pp. 324–330. https://doi.org/10.1016/j.pupt.2007.08.001
7. Mueller E., Drori S., Aiyer A., Yie J., Sarraf P., Chen H. [et al.]. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. Journal of Biological Chemistry, 2002, vol. 277, no. 44, pp. 41925–41930. https://doi.org/10.1074/jbc.M206950200
8. Brunmeir R., Xu F. Functional regulation of PPARs through post-translational modifcations. International Journal of Molecular Sciences, 2018, vol. 19, no. 6, аrt. 1738. https://doi.org/10.3390/ijms19061738
9. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling, 2003, vol. 15, no. 4, pp. 355–366. https://doi.org/10.1016/S0898-6568(02)00115-8
10. Zoete V., Grosdidier A., Michielin O. Peroxisome proliferator-activated receptor structures: ligand specifcity, molecular switch and interactions with regulators. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007, vol. 1771, no. 8, pp. 915–925. https://doi.org/10.1016/j.bbalip.2007.01.007
11. Sonoda J., Pei L., Evans R. M. Nuclear receptors: decoding metabolic disease. FEBS Letters, 2008, vol. 582, no. 1, pp. 2–9. https://doi.org/10.1016/j.febslet.2007.11.016
12. Xu H. E., Lambert M. H., Montana V. G., Parks D. J., Blanchard S. G., Brown P. J. [et al.]. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Molecular Cell, 1999, vol. 3, no. 3, pp. 397–403. https://doi.org/10.1016/S1097-2765(00)80467-0
13. Krey G., Braissant O., L’Horset F., Kalkhoven E., Perroud M., Parker M. G., Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identifed as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molecular Endocrinology, 1997, vol. 11, no. 6, pp. 779–791. https://doi.org/10.1210/mend.11.6.0007
14. Watt M. J., Southgate R. J., Holmes A. G., Febbraio M. A. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1 alpha in human skeletal muscle, but not lipid regulatory genes. Journal of Molecular Endocrinology, 2004, vol. 33, no. 2, pp. 533–544. https://doi.org/10.1677/jme.1.01499
15. Siersbaek R., Nielsen R., Mandrup S. PPARgamma in adipocyte differentiation and metabolism – novel insights from genome-wide studies. FEBS Letters, 2010, vol. 584, no. 15, pp. 3242–3249. https://doi.org/10.1016/j.febslet.2010.06.010
16. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, vol. 137, no. 1, pp. 354–366. https://doi.org/10.1210/endo.137.1.8536636
17. Lefebvre P., Chinetti G., Fruchart J.-Ch., Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. Journal of Clinical Investigation, 2006, vol. 116, no. 3, pp. 571–580. https://doi.org/10.1172/JCI27989
18. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-Ch. Mechanism of action of fbrates on lipid and lipoprotein metabolism. Circulation, 1998, vol. 98, no. 19, pp. 2088–2093. https://doi.org/10.1161/01.cir.98.19.2088
19. Kersten S., Mandard S., Escher P., Gonzalez F. J., Tafuri S., Desvergne B., Wahli W. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB Journal, 2001, vol. 15, no. 11, pp. 1971–1978. https://doi.org/10.1096/fj.01-0147com
20. Yang Y., Gocke A. R., Lovett-Racke A., Drew P. D., Racke M. K. PPAR alpha regulation of the immune response and autoimmune encephalomyelitis. PPAR Research, 2008, vol. 2008, art. ID 546753. https://doi.org/10.1155/2008/546753
21. Sun Y., Alexander S. P. H., Kendall D. A., Bennett A. J. Cannabinoids and PPARalpha signaling. Biochemical Society Transactions, 2006, vol. 34, no. 6, pp. 1095–1097. https://doi.org/10.1042/BST0341095
22. Pandey N. R., Renwick J., Misquith A., Sokoll K., Sparks D. L. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion. Biochemistry, 2008, vol. 47, no. 6, pp. 1579–1587. https://doi.org/10.1021/bi702148f
23. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.-M., Saladin R. [et al.]. The organization, promoter analysis, and expression of the human PPARgamma gene. Journal of Biological Chemistry, 1997, vol. 272, no. 30, pp. 18779–18789. https://doi.org/10.1074/jbc.272.30.18779
24. Han T., Lv Y., Wang S., Hu T., Hong H., Fu Z. PPARγ overexpression regulates cholesterol metabolism in human L02 hepatocytes. Journal of Pharmacological Sciences, 2019, vol. 139, no. 1, pp. 1–8. https://doi.org/10.1016/j.jphs.2018.09.013
25. Wang S., Dougherty E. J., Danner R. L. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacological Research, 2016, vol. 111, pp. 76–85. https://doi.org/10.1016/j.phrs.2016.02.028
26. Nedergaard J., Petrovic N., Lindgren E. M., Jacobsson A., Cannon B. PPARgamma in the control of brown adipocyte differentiation. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 2005, vol. 1740, no. 2, pp. 293–304. https://doi.org/10.1016/j.bbadis.2005.02.003
27. Barson J. R., Karatayev O., Chang G.-Q., Johnson D. F., Bocarsly M. E., Hoebel B. G., Leibowitz S. F. Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol, 2009, vol. 43, no. 6, pp. 433–441 https://doi.org/10.1016/j.alcohol.2009.07.003
28. Stopponi S., Somaini L., Cippitelli A., Cannella N., Braconi S., Kallupi M. [et al.]. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biological Psychiatry, 2011, vol. 69, no. 7, pp. 642–649. https://doi.org/10.1016/j.biopsych.2010.12.010
29. Stopponi S., de Guglielmo G., Somaini L., Cippitelli A., Cannella N., Kallupi M. [et al.]. Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcoholism: Clinical and Experimental Research, 2013, vol. 37, no. 8, pp. 1351–1360. https://doi.org/10.1111/acer.12091
30. Sorge R. E., Mapplebeck J. C. S., Rosen S., Beggs S., Taves S., Alexander J. K. [et al.]. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nature Neuroscience, 2015, vol. 18, no. 8, pp. 1081–1083. https://doi.org/10.1038/nn.4053
31. Blednov Y. A., Benavidez J. M., Black M., Ferguson L. B., Schoenhard G. L., Goate A. M. [et al.]. Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. Alcoholism: Clinical and Experimental Research, 2015, vol. 39, no. 1, pp. 136–145. https://doi.org/10.1111/acer.12610
32. Blednov Y. A., Black M., Benavidez J. M., Stamatakis E. E., Harris R. A. PPAR agonists: I. Role of receptor subunits in alcohol consumption in male and female mice. Alcoholism: Clinical and Experimental Research, 2016, vol. 40, no. 3, pp. 553–562. https://doi.org/10.1111/acer.12976
33. Blednov Y. A., Black M., Benavidez J. M., Stamatakis E. E., Harris R. A. PPAR agonists: II. Fenofbrate and tesaglitazar alter behaviors related to voluntary alcohol consumption. Alcoholism: Clinical and Experimental Research, 2016, vol. 40, no. 3, pp. 563–571. https://doi.org/10.1111/acer.12972
34. Karahanian E., Quintanilla M. E., Fernandez K., Israel Y. Fenofbrate – a lipid-lowering drug – reduces voluntary alcohol drinking in rats. Alcohol, 2014, vol. 48, no. 7, pp. 665–670. https://doi.org/10.1016/j.alcohol.2014.08.004
35. Bardina L. R., Pron’ko P. S., Satanovskaya V. I., Alieva E. V. Effects of catalase activators and inhibitors on ethanol pharmacokinetics and the activity of enzymes involved in metabolism of ethanol and acetaldehyde in the liver and brain of rats. Biomeditsinskaya khimiya [Biomedical chemistry], 2010, vol. 56, no. 4, pp. 499–505 (in Russian).
36. Ferguson L. B., Most D., Blednov Y. A., Harris R. A. PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption. Neuropharmacology, 2014, vol. 86, pp. 397–407 https://doi.org/10.1016/j.neuropharm.2014.06.024
37. Shlyakhtun A. G., Buben A. L., Loban’ Yu. V., Satanovskaya V. I., Pron’ko P. S. New pharmacological approaches in the treatment of alcohol dependence: PPAR receptor agonists. Sovremennye problemy biokhimii i molekulyarnoi biologii: sbornik nauchnykh statei (Grodno, 17–18 maya 2018 goda) [Modern problems of biochemistry and molecular biology: a collection of scientifc articles (Grodno, May 17–18, 2018)]. Minsk, 2018, pp. 730–735 (in Russian).
38. Kelley K. W., Dantzer R. Alcoholism and inflammation: neuroimmunology of behavioral and mood disorders. Brain, Behavior, and Immunity, 2011, vol. 25, suppl. 1, pp. S13–S20. https://doi.org/10.1016/j.bbi.2010.12.013
39. Blanquart C., Barbier O., Fruchart J. Ch., Staels B., Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2003, vol. 85, no. 2–5, pp. 267–273. https://doi.org/10.1016/S0960-0760(03)00214-0
40. Aleshin S., Grabeklis S., Hanck T., Sergeeva M., Reiser G. Peroxisome proliferator-activated receptor (PPAR)- gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. Molecular Pharmacology, 2009, vol. 76, no. 2, pp. 414–424. https://doi.org/10.1124/mol.109.056010
41. Nan Y.-M., Wang R.-Q., Fu N. Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease. World Journal of Gastroenterology, 2014, vol. 20, no. 25, pp. 8055–8060. https://doi.org/10.3748/wjg.v20.i25.8055
42. Kong L., Ren W., Li W., Zhao S., Mi H., Wang R., Zhang Y., Wu W., Nan Y., Yu J. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids in Health and Diseases, 2011, vol. 10, art. 246. https://doi.org/10.1186/1476-511X-10-246
43. Wu C., Gilroy R., Taylor R., Olyaee M., Abdulkarim B., Forster J., O’Neil M., Damjanov I., Wan Y.-J. Y. Alteration of hepatic nuclear receptor- mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology, 2011, vol. 54, no. 6, pp. 1966–1974. https://doi.org/10.1002/hep.24645
44. Zhang W., Sun Q., Zhong W., Sun X., Zhou Z. Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic steatosis and inflammation in mice. Alcoholism: Clinical and Experimental Research, 2016, vol. 40, no. 5, pp. 988–999. https://doi.org/10.1111/acer.13049
45. Liu S., Wu H.-J., Zhang Z.-Q., Chen Q., Liu B., Wu J.-P., Zhu L. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. European Journal of Pharmacology, 2011, vol. 650, no. 1, pp. 384–389. https://doi.org/10.1016/j.ejphar.2010.09.082
46. Zhang F., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fbrogenesis. Cellular Signalling, 2012, vol. 24, no. 3, pp. 596–605. https://doi.org/10.1016/j.cellsig.2011.11.008
47. Pang M., de la Monte S. M., L. Longato, M. Tong, He J., Chaudhry R., Duan K., Ouh J., Wands J. R. PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. Journal of Hepatology, 2009, vol. 50, no. 6, pp. 1192–1201. https://doi.org/10.1016/j.jhep.2009.01.021
48. Khoo N. K. H., Hebbar S., Zhao W., Moore S. A., Domann F. E., Robbins M. E. Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy. Redox Biology, 2013, vol. 1, no. 1, pp. 70–79. https://doi.org/10.1016/j.redox.2012.12.006
49. Liu X., Jang S. S., An Z., Song H., Kim W.-D., Yu J.-R., Park W.-Y. Fenofbrate decreases radiation sensitivity
50. via peroxisome proliferator-activated receptor α-mediated superoxide dismutase induction in HeLa cells. Radiation
51. Oncology Journal, 2012, vol. 30, no. 2, pp. 88–95. https://doi.org/10.3857/roj.2012.30.2.88
Review
For citations:
Semenenya I.N., Shlyahtun A.H., Raduta H.F. Role of peroxisome proliferator-activated receptors in the control of alcohol dependence and concomitant liver pathology. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(2):244-256. (In Russ.) https://doi.org/10.29235/1814-6023-2019-16-2-244-256
Views: 695
Email this article 